Xcout Intel
Amplio Pharma
Amplio Pharma is a pharmaceutical company founded in 2020 that develops proprietary drug products to significantly amplify the efficacy of existing pharmaceutical treatments. The company is headquartered in Leiden, Netherlands.
Subscribe to see Amplio Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Amplio Pharma at a glance
Amplio Pharma is a biotechnology company headquartered in Netherlands. Its most recent funding round, Seed, raised $400,000 in April 2025. Xcout tracks 12 named people at Amplio Pharma, including Lars Bukhave-Rasmussen (Chief Financial Officer).
Amplio Pharma leadership
- Lars Bukhave-RasmussenChief Financial Officer
- Marguerite MensonidesCEO co-founder
- Charlott BrunmarkCSO Non-Clinical co-founder
- Karin von WachenfeldtCSO Clinical co-founder
- Henrik FengerVP Photonamic
- Bart WuurmanDirector Business Development
6 more named people on record for Amplio Pharma, with roles, board committees and tenure — see the full roster →
Amplio Pharma funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $400,000 | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Amplio Pharma competitors
A few of Amplio Pharma's closest competitors — see the full list of competitors and alternatives →
Amplica Bio, Inc. is a biotechnology company that develops next-generation biologics and therapies aimed at targeting difficult diseases. The company engages in drug engineering to address challenging therapeutic targets.
Apollo Therapeutics is a biopharmaceutical company with headquarters located in Cambridge, United Kingdom, alongside offices in Boston, Massachusetts. The company advances breakthrough science to build a portfolio of innovative therapeutics.
Amporin Pharmaceuticals AG is a Swiss biotechnology company founded in Basel in 2024. The firm focuses on developing a new class of small-molecule drugs designed to target toxic membrane mechanisms.
Scenic Biotech is a biotechnology company headquartered in Amsterdam, Netherlands, that advances modifier therapy as an approach to treating genetic disorders by uncovering novel genome pathways.
AMPLY Discovery is a biotechnology company based in the UK. This biotech firm focuses on developing a pipeline of first-in-class drugs by exploring the 98% of the genome largely ignored by other drug developers. It is headquartered in Belfast.
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP). Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.
Get Amplio Pharma's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Amplio Pharma in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access